Point72 Asia (Singapore) Pte. Ltd. Immunome Inc. Call Options Transaction History
Point72 Asia (Singapore) Pte. Ltd.
- $480 Billion
- Q2 2024
Call Options
0 transactions
Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
---|
Others Institutions Holding IMNM
# of Institutions
115Shares Held
43.4MCall Options Held
67.2KPut Options Held
65.9K-
Redmile Group, LLC San Francisco, CA4.89MShares$69.5 Million3.86% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA3.88MShares$55.2 Million1.66% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD3.88MShares$55.2 Million0.03% of portfolio
-
Black Rock Inc. New York, NY3.76MShares$53.5 Million0.0% of portfolio
-
Janus Henderson Group PLC London, X03.16MShares$45 Million0.02% of portfolio
About Immunome Inc.
- Ticker IMNM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 12,127,400
- Market Cap $172M
- Description
- Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product ca...